{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:43:06Z","timestamp":1777934586008,"version":"3.51.4"},"reference-count":18,"publisher":"SAGE Publications","issue":"7","license":[{"start":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T00:00:00Z","timestamp":1673568000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Capecitabine is a molecule of choice in the therapeutic arsenal of anticancer drugs used in Morocco for the treatment of breast cancer and colorectal cancer. Its frequent use imposes a follow-up and a post-prescription monitoring of the treatment modalities as well as the adverse events that may occur following its administration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The objective of this study is to evaluate the level of knowledge of patients in the day hospital of an oncology facility about their treatment with capecitabine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>This is a prospective study conducted over a period of 2 months (January\u2013February 2022) at the day hospital in the National Institute of Oncology in Rabat, and it was conducted using a questionnaire in order to evaluate patients\u2019 knowledge about their treatment with capecitabine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>This study involved 95 patients, 76% claimed to have ever received pharmaceutical advice on capecitabine treatment. The main indications were colorectal and breast cancer. Ninety seven percent knew the indication for capecitabine and the action of the molecule on the relevant tumor. Eighty three percent receiving capecitabine therapy reported the occurrence of side effects and hand-foot syndrome was the most reported in 31.2% of the total listed side effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Capecitabine is an oral treatment of choice for colorectal and breast cancer in Morocco. Therapeutic education happens to be an effective tool in order to guarantee the best effectiveness and manage the possible side effects that can occur during the treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552221150802","type":"journal-article","created":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T11:04:25Z","timestamp":1673607865000},"page":"1708-1714","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Assessment of patients\u2019 knowledge of their treatment with capecitabine at the National Institute of Oncology in Rabat"],"prefix":"10.1177","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3011-145X","authenticated-orcid":false,"given":"Chaimaa","family":"Nouibi","sequence":"first","affiliation":[{"name":"Faculty of Medicine and Pharmacy, Mohammed V University, Rabat, Morocco"},{"name":"Ibn Sina University Hospital, Rabat, Morocco"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8142-1218","authenticated-orcid":false,"given":"Ali","family":"Cherif Chefchaouni","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Pharmacy, Mohammed V University, Rabat, Morocco"},{"name":"Ibn Sina University Hospital, Rabat, Morocco"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hafsa","family":"Bechar","sequence":"additional","affiliation":[{"name":"National Institute of Oncology, Department of Pharmacy, Ibn Sina University Hospital, Rabat, Morocco"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed Jaouad","family":"Belahcen","sequence":"additional","affiliation":[{"name":"National Institute of Oncology, Department of Pharmacy, Ibn Sina University Hospital, Rabat, Morocco"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Younes","family":"Rahali","sequence":"additional","affiliation":[{"name":"National Institute of Oncology, Department of Pharmacy, Ibn Sina University Hospital, Rabat, Morocco"},{"name":"Team of Formulation and Quality Control of Health Products, Faculty of Medicine and Pharmacy, Mohammed V University, Rabat, Morocco"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2023,1,13]]},"reference":[{"key":"bibr1-10781552221150802","unstructured":"International Agency for Research on Cancer. Latest global cancer data: Cancer burden rises to 19.3 million new cases and 10.0 million cancer deaths in 2020, https:\/\/www.iarc.who.int\/fr\/news-events\/latest-global-cancer-data-cancer-burden-rises-to-19-3-million-new-cases-and-10-0-million-cancer-deaths-in-2020\/ (2020, accessed 31 May 2022)."},{"key":"bibr2-10781552221150802","unstructured":"International Agency for Research on Cancer. 504-morocco-fact-sheets, https:\/\/gco.iarc.fr\/today\/data\/factsheets\/populations\/504-morocco-fact-sheets.pdf (2021, accessed 25 March 2022)."},{"key":"bibr3-10781552221150802","unstructured":"Association Marocaine de Recherche et De Formation en Oncologie M\u00e9dicale. Bulletin Marocain de l\u2019Oncologie Suppl\u00e9ment 1, No. 10, Juin 2019 GUIDE DES PROTOCOLES THERAPEUTIQUES EN ONCOLOGIE 4 \u00e8me \u00e9dition - version Juin 2019, http:\/\/amfrom.ma\/publications?part_ind=refg (2019, accessed 26 March 2022)."},{"key":"bibr4-10781552221150802","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.12-2-152"},{"key":"bibr5-10781552221150802","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.8.2282"},{"key":"bibr6-10781552221150802","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1612645"},{"key":"bibr7-10781552221150802","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2011.546342"},{"key":"bibr8-10781552221150802","unstructured":"Chemocare. Capecitabine - drug information, https:\/\/chemocare.com\/chemotherapy\/drug-info\/capecitabine.aspx (2012, accessed 27 March 2022)."},{"key":"bibr9-10781552221150802","doi-asserted-by":"publisher","DOI":"10.1016\/j.phclin.2020.11.001"},{"key":"bibr10-10781552221150802","first-page":"107815522110602","author":"Chefchaouni AC","year":"2021","journal-title":"J Oncol Pharm Pract"},{"key":"bibr11-10781552221150802","doi-asserted-by":"publisher","DOI":"10.1177\/10781552221118846"},{"key":"bibr12-10781552221150802","doi-asserted-by":"publisher","DOI":"10.1111\/j.1751-7176.2008.07572.x"},{"key":"bibr13-10781552221150802","doi-asserted-by":"publisher","DOI":"10.1016\/j.revmed.2018.03.248"},{"key":"bibr14-10781552221150802","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejon.2004.06.006"},{"key":"bibr15-10781552221150802","doi-asserted-by":"publisher","DOI":"10.1016\/j.phclin.2019.10.011"},{"key":"bibr16-10781552221150802","unstructured":"Oncohealth Institute. CAPECITABINE, http:\/\/www.oncohealth.eu\/en\/patient-area\/understanding-cancer\/patient-information-support\/general-information\/treatment\/chemotherapy\/listado-farmacos\/capecitabine (2017, accessed 24 March 2022)."},{"key":"bibr17-10781552221150802","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12474"},{"key":"bibr18-10781552221150802","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/7207983"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552221150802","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552221150802","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552221150802","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:27:51Z","timestamp":1777688871000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552221150802"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,13]]},"references-count":18,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["10.1177\/10781552221150802"],"URL":"https:\/\/doi.org\/10.1177\/10781552221150802","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,13]]}}}